Enhanced natural killer activity and production of pro-inflammatory cytokines in mice selected for high acute inflammatory response (AIRmax)

Immunology

Volumn 120, Issue 3, 2007, Pages 372-379

  Castoldi, Lindsey ^a   Golim, Marjorie Assis ^a   Filho, Orlando Garcia Ribeiro ^b   Romagnoli, Graziela Gorete ^a   Ibañez, Olga Célia Martinez ^b   Kaneno, Ramon ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Cytotoxicity; Immunogenetics; Inflammation; Innate immunity; Natural killer cells

Indexed keywords

ALPHA2 INTEGRIN; CD3 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOLYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; MALE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, NATURAL; IMMUNOPHENOTYPING; INFLAMMATION; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; MALE; MICE; SELECTION (GENETICS); SPECIES SPECIFICITY; SPLEEN; T-LYMPHOCYTE SUBSETS;

EID: 33846895042     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02513.x     Document Type: Article

References (54)

1. Ibañez OM, Stiffel C, Ribeiro OG, et al. Genetics of nonspecific immunity. I. Bidirectional selective breeding of lines of mice endowed with maximal or minimal inflammatory responsiveness. Eur J Immunol 1992; 22:2555-63.
2. Biozzi G, Ribeiro OG, Saran A, et al. Effect of genetic modification of acute inflammatory responsiveness on tumorigenesis in the mouse. Carcinogenesis 1998; 19:337-46.
3. Maria DA, Ribeiro OG, Pizzocaro KF, et al. Resistance to melanoma metastases in mice selected for high acute inflammatory response. Carcinogenesis 2001; 22:337-42.
4. Ribeiro OG, Cabrera WH, Maria DA, et al. Genetic selection for high acute inflammatory response confers resistance to lung carcinogenesis in the mouse. Exp Lung Res 2005; 31:105-16.
5. Ribeiro OG, Maria DA, Adriouch S, Pechberty S, Cabrera WH, Morisset J, Ibañez OM, Semen M. Convergent alteration of granulopoiesis, chemotactic activity, and neutrophil apoptosis during mouse selection for high acute inflammatory response. J Leukocyte Biol 2003; 31:105-16.
6. Maria DA, Manenti G, Galbiati F, et al. Pulmonary adenoma susceptibility 1 (Pas 1) locus affects inflammatory response. Oncogene 2003; 22:426-32.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
8. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
9. Gallin JI, Snyderman R. Inflammation: Basis, Principles and Clinical Correlates, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 1999.
10. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-92.
11. Takaoka A, Hayakama S, Yanai H, et al. Integration of interferon-α/β signaling to p53 responses in tumor suppression and antiviral defence. Nature 2003; 424:516-23.
12. Divino CM, Chen SH, Yang W, Thung S, Brower ST, Woo SLC. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treatment 2000; 60:129-34.
13. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002; 23:201-8.
14. Vigar ND, Cabrera WH, Araujo LMN, Ribeiro OG, Ogata TRP, Siqueira M, Ibañez OM, De Franco M. Pristane-induced arthitis in mice selected for maximal or minimal acute inflammatory reaction. Eur J Immunol 2000; 30:431-7.
15. Herberman RB, Hiserodt J, Vujanovic N, et al. Lymphokineactivated killer cell activity: characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 1987; 8:178.
16. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
17. Miller JS. The biology of natural killer cells in cancer, infection and pregnancy. Exp Hematol 2001; 29:1157-68.
18. Seaman WE. Natural killer cells and natural killer T cells (review). Am Coll Rheum 2000; 43:1204-17.
19. Kaneno R. Role of natural killer cells in antitumor resistance. ARBS 2005; 7:127-48.
20. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nature Rev Immunol 2002; 2:735-47.
21. Rener M, Müllbacher A. Granzymes in cytolytic lymphocytes - to kill a killer? Immunol Cell Biol 2004; 82:161-9.
22. Wallach D, Bigda J, Engelman H. The tumor necrosis factor (TNF) family and related molecules. In: Theze, J, ed. The Cytokine Network and Immune Functions. Oxford: Oxford University Press, 1999:251-61.
23. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997; 4:32-40.
24. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 1999; 5:90-6.
25. Kos FJ, Engleman EG. Immune regulation. A critical link between NK cells and CTLs. Immunol Today 1996; 17:174-6.
26. Geldhof A, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 2002; 100:4049-58.
27. Kaneno R, Duarte AJS, Borelli A. Natural killer activity in the experimental privational rickets. Immunol Lett 2002; 81:183-9.
28. Takeda K, Hayakawa Y, Atsuta M, et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 2000; 12:909-14.
29. 2 integrin, very late antigen-2). J Immunol 2001; 167:1141-4.
30. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7:704-10.
31. Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem 1991; 45:335-9.
32. Timonen T, Patarroyo M, Gahmberg CG. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol 1988; 141:1041-6.
33. Schierloh P, Alemán M, Yokobori N, Alves L, Roldán N, Del Abbate EC, Sasiain M, de la Barrera S. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activaction. Immunology 2005; 116:541-52.
34. Abdool K, Cretney E, Brooks AD, et al. NK cells use NKG@D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol 2006; 177:2575-83.
35. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176:1387-98.
36. Jun Ha S, Lee CH, Lee SB, Kim CM, Jang KL, Shin HS, Sung YC. A novel function of IL-12p40 as a chemotactic molecule for macrophages. J Immunol 1999; 163:2902-8.
37. Shiraki M, Aihara H, Kinouchi H et al. IL-12p40 prevents the development of chronic enterocolitis in IL-10-deficient mice. Lab Invest 2004; 84:1491-500.
38. Trinchieri G. Interleukin 12. In: Theze, J, ed. The Cytokine Network and Immune Functions. Oxford: Oxford University Press, 1999:97-103.
39. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13:135-41.
40. Watanabe N, Niitsu Y, Umero H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant tumour necrosis factor and hyperthermia. Cancer Res 1988; 48:650-3.
41. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas DG, Papmichail M. Compromised anti-tumor response in tumor necrosis factor-α knockout mice. Eur J Immunol 2000; 30:1957-1.
42. Sato T, Yamauchi N, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, Watanabe N, Niitsu Y. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res 1998; 58:1677-83.
43. Schmitt M, Ikeda H, Nagata Y, Gu X, Wang L, Kuribayashi K, Shiku H. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int J Cancer 1997; 72:505-11.
44. Langrish CL, McKenzie BS, Wilson NJ, Malefyt RW, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202:96-105.
45. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev Immunol 2003; 3:133-46.
46. Carneiro A, Ribeiro OG, De Franco M, Cabrera WHK, Vorraro F, Siqueira M, Ibañez OM, Starobinas N. Local inflammatory reaction induced by Bothrops jararaca venom differs in mice selected for acute inflammatory response. Toxicon 2002; 40:1571-9.
47. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas-ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002; 168:3484-92.
48. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunoth 2001; 24:392-407.
49. Pretolani M, Stordeur P, Golman M. Interleukin 10. In: Theze, J, ed. The Cytokine Network and Immune Functions. Oxford: Oxford University Press, 1999:45-50.
50. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nature Rev 2003; 3:253-7.
51. Fundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997; 180:55-61.
52. Shibata Y, Foster LA, Kurimoto M et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-γ-inducing factors but enhances NK cell production of IFN-γ. J Immunol 1998; 161:4283-8.
53. Zheng LM, Ojcius DM, Garaud F et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184:579-84.
54. + T-cell effector function in situ. Blood 2001; 98:2143-51.